Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

Journal of Immunology

Volumn 169, Issue 1, 2002, Pages 350-358

  Zwaveling, Sander ^a   Ferreira Mota, Sandra C ^a   Nouta, Jan ^a   Johnson, Mark ^a   Lipford, Grayson B ^a   Offringa, Rienk ^a   Van der Burg, Sjoerd H ^a   Melief, Cornelis J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINYLALANYLHISTIDINYLTYROSYLASPARAGINYLISOLEUCYLVALYLTHREONYLPHENYLALANIN AMIDE; CANCER VACCINE; CD8 ANTIGEN; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PEPTIDE E7; PROTEIN CPG; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL SPECIFICITY; CONTROLLED STUDY; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG SAFETY; ENDOCYTOSIS; EPITOPE MAPPING; ERADICATION THERAPY; GOOD MANUFACTURING PRACTICE; HUMAN PAPILLOMAVIRUS TYPE 16; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; T LYMPHOCYTE ACTIVATION; UTERINE CERVIX CANCER; VACCINATION; VIRUS CARCINOGENESIS; WART VIRUS;

EID: 0036644556     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.1.350     Document Type: Article

References (58)

1. Papillomavirus infections: A major cause of human cancers
2. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective
3. Strategies for immunotherapy of cancer
4. The natural history of CIN I lesions
5. Human papillomavirus infection is transient in young women: A population-based cohort study
6. Natural history of cervicovaginal papillomavirus infection in young women
7. Immunohistologic analysis of the phenomenon of spontaneous regression of numerous flat warts
8. Immunological events in regressing genital warts
9. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions
10. Incidence of venereal warts in human immunodeficiency virus-infected and uninfected women
11. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3
12. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive
13. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
14. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma
15. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7
16. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
17. + T helper cell responses in tumor immunity
18. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
19. + helper T cells are required for resistance to a highly metastatic murine tumor
20. Role of helper T-lymphocytes in rejection of UV-induced murine skin cancers
21. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
22. + T-helper and a T-killer cell
23. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
24. High-level IL-12 production by human dendritic cells requires two signals
25. Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection: Protection by T cells is MHC-restricted and MHC-regulated: A model for MHC-disease associations
26. + CTL in vivo with peptide vaccine constructs
27. Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides
28. Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus
29. + T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization
30. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells
31. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization
32. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses
33. Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A
34. Monophosphoryl lipid A as an adjuvant: Past experiences and new directions
35. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy
36. Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines
37. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides
38. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins
39. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: Identification of 3 human leukocyte antigen class II-restricted epitopes
40. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells
41. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen
42. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells
43. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
44. Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T-lymphocyte epitopes
45. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures
46. Dendritic cell maturation is required for initiation of the immune response
47. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes
48. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens
49. Qualitative changes accompany memory T cell generation: Faster, more effective responses at lower doses of antigen
50. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
51. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model
52. An immunodominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 class II-restricted help for itself
53. + T-cell clones from congenital rubella syndrome patients with IDDM recognize overlapping GAD65 protein epitopes: Implications for HLA class I and II allelic linkage to disease susceptibility
54. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients
55. Alternative antigen processing pathways in anti-infective immunity
56. Antigen decoding by T lymphocytes: From synapses to fate determination
57. Candidate HIV type 1 multideterminant cluster peptide-P18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization
58. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide